

Peripheral Neuropathy


SAPMEA ECHO Neurology 14 April 2022

PANEL MEMBERS

Dr Jessica Hafner – Consultant Neurologist, CALHN
Mirjana Culibrk – Senior Pharmacist, FMC Stroke & Neurology, SALHN
Matthew Gliddon – Senior Physiotherapist, Neurology & Stroke, CALHN

Topic Overview

- Approach to neuropathy
 - History and examination
 - First line evaluation
 - Red flags
 - Second line evaluation
 - When to order NCS
- Management
 - Prevent progression
 - Prevent complications
 - Minimise disability
 - Neuropathic pain
 - Medical marijuana role



Approach to peripheral neuropathy

Common problem with > 200 possible causes



- Neuropathy Assessment
 - History
 - Symptoms (numb, pain, weak)
 - Progression and disability
 - Red flags screening
 - Nutrition & supplements
 - Alcohol use
 - Examination of UL & LL
 - Tone
 - Power
 - Sensation vibration and temperature
 - Reflexes

Approach to peripheral neuropathy

- Basic Evaluation
 - Screening for common treatable causes
 - Blood tests
 - Alcohol use
 - Check medication/supplement use
 - Nerve conduction studies
 - Type (axonal/demyelinating)
 - Pattern
 - Severity

INITIAL EVALUATION OF LENGTH-DEPENDENT SYMMETRIC AXONAL POLYNEUROPATHY

- Vitamin B12
- Fasting glucose and HbA1C +/- 2hr OGTT
- EPG/IEPG + serum free light chain assay
- > Electrolytes, urea, creatinine
- Liver function tests (esp. GGT)
- Calcium, magnesium, phosphate
- > Full blood count
- Erythrocyte sedimentation rate and C reactive protein
- > Thyroid function tests
- Autoimmune screen (ANA, ENA, ANCA, RF)
- Coeliac serology

"Active B12" not validated in general population.

Treat neuropathy patients with low or borderline total

B12 levels.

Neuropathy Red Flags

- Acute/subacute onset
- Rapidly progressive (days/weeks)
- Disabling
- Motor predominant
- Painful
- Systemic features (e.g. wt loss)
- Young age at onset
- Non-length dependent (UL > LL or asymmetrical)
- Dysautonomia

These are clues to autoimmune (GBS, CIDP), vasculitis, paraneoplastic, amyloidosis/myeloma, hereditary and other potentially life-threatening or severely disabling neuropathies. Fortunately, 'red flag' much rarer than the usual suspects



Approach to peripheral neuropathy

SECONDARY EVALUATION OF LENGTH-DEPENDENT SYMMETRIC AXONAL POLYNEUROPATHY

- Additional autoimmune work up (anti-dsDNA Ab, serum ACE)
- ➤ HBV + HCV + cryoglobulins
- Syphilis serology
- > HIV serology

- Not all patients without a cause need secondary evaluation
- Guided by level of clinical suspicion and clinical severity/progression

What can a nerve conduction study tell me?


- Focal neuropathy
 - Carpal tunnel lesion
 - Ulnar neuropathy at elbow
- Polyneuropathy
 - Is it symmetrical, length dependent?
 - Is it sensory and/or motor?
 - Is it axonal or demyelinating?
- Other disorders
 - Amyotrophic lateral sclerosis
 - Myasthenia gravis
 - Radiculopathy

- What can't it tell you?
 - Small fibre and/or autonomic neuropathy
 - Exclude mild neuropathy
 - Cause of neuropathy

When to order:

- Suspected new diagnosis of peripheral neuropathy
 - Esp. if no obvious cause if + 'red flags'
- Suspected focal neuropathy
 - At onset to confirm Dx (+/- rule out important DDx)
 - If invasive treatment being considered (e.g. CTS, ulnar neuropathy)

Management



nutrition

Allied health MANAGMENT

- Exercise can help to reduce Neuropathic pain intensity
- Focus on supportive care
 - Reduce falls risk (internal/external factors)
 - Splints and braces (many types)
 - adaptive aids as indicated
 - Reduce skin injury risk
- Lower limb:
 - Foot drop: AFO
 - Ankle instability ASO







Allied health management

Upper limb: Impaired dexterity → Modified cutlery (Or lagging)



- Carpal tunnel: resting night splints (Futuro)
- Radial Nerve Palsy: Futuro, custom, sometimes active spinic



Thumb MCP support for OA









ThumSling

North Coast Coolcomfort Neoprene


Push Brace Actimove Rhizo Forte Custom Made Splint

Community BASED follow-up

- Day rehabilitation services
 - Access for multi-disciplinary allied health (PT/EP/OT/SP/Orthotics/Nutrition and Diet
 - Located within LHN's
- Orthotics and Prosthetics (Direct referra
- Country referral unit
- Strength for life (50+)
 - EP/Fitness trainer/Aqua



Neuropathic pain management



Acute neuropathic pain

- May take up to 1 week to achieve adequate pain relief
- Uptitrate dose slowly in community (in hospital sometimes titrated faster with monitoring)
- Always have a plan for reassessment of pain, and tapering and stopping adjuvants.

Chronic neuropathic pain

- Review the analgesic efficacy after 4 to 6 weeks
- If adjuvant monotherapy provides a partial response, but pain relief is still inadequate, consider adding a second adjuvant.
- If effective, the adjuvant(s) may be continued short- to moderate-term (eg up to 12 weeks). Some patients with permanent nerve damage (eg spinal cord injury) may require therapy for longer than 12 weeks, with a supported self-management approach. Trial deprescribing every 3 to 6 months to assess ongoing efficacy attributable to the adjuvant, and reduce the risk of long-term adverse effects

Drugs	Acute pain (nociceptive)	Neuropathic pain	Chronic pain (nociceptive with/without neuropathic)
paracetamol	effective	less effective	effective
NSAIDs	effective	less effective	effective
antidepressants (eg low dose TCAs, duloxetine) antiepileptics (eg gabapentin,	rarely used	may be effective; first and second line	may be effective if neuropathic component
pregabalin, carbamazepine)			
opioids	effective	may be effective; third line	may be effective but limited or no benefit long- term (>90 days) for non- cancer pain

Most commonly prescribed adjuvants are:

- TCAs—amitriptyline, nortriptyline
- Gabapentinoids—gabapentin, pregabalin
- SNRIs—duloxetine, venlafaxine
 - ✓ Remember the basics (use simple analgesia)
 - ✓ Start low, titrate doses slowly
 - ✓ Monitor side effects
 - ✓ Monitor effectiveness (allow time!)
 - ✓ Re-assess
 - √ Have a plan for tapering/deprescribing

Choice of adjuvant will depend on individual patient factors (comorbidities, weight gain, sedation, previous experience, current medications, cost) and adverse effect profile

Drug class (commonly used drugs)	Class considerations	Individual drug considerations
gabapentinoids (gabapentin, pregabalin)	more rapid onset of analgesia compared to TCAs or SNRIs potential for misuse, dependence and withdrawal sedation is common can cause respiratory depression, especially when co-administered with an opioid	pregabalin has a more convenient dosing schedule and more predictable absorption than gabapentin if low doses are required, gabapentin may be preferred because it is less potent than pregabalin
serotonin and noradrenaline reuptake inhibitor (duloxetine, venlafaxine)	sedation is rare can cause <u>serotonin toxicity</u>	venlafaxine is associated with a higher incidence of adverse effects than duloxetine
tricyclic antidepressant (amitriptyline, nortriptyline)	often poorly tolerated due to <u>anticholinergic effects</u> anticholinergic effects may increase the risk of dementia in older people sedation is common	amitriptyline is the most sedating TCA and has the highest rate of anticholinergic effects nortriptyline is the least sedating TCA and may be preferred if combined with an opioid

- Topical capsaicin and lignocaine patches have weak evidence in the treatment of peripheral neuropathic pain
- lacosamide, lamotrigine, oxcarbazepine, phenytoin, sodium valproate, topiramate -> limited evidence

Management: Neuropathic Pain

- The most common reasons I see for neuropathy pain management 'failing'
- ➤ Not using basics with the extras (i.e. not using paracetamol with a neuropathic pain medication)
- Starting with high doses or increasing too quickly leading to side effects
- Using doses that are too low and therefore not effective
- Giving up on a medication too quickly before it has had chance to work
- Using a medication 'as needed' instead of regularly
- Unrealistic expectations of treatment



Medical photo created by freepik - www.freepik.com

Management

- Vitamin supplements
 - Only in proven deficiency
 - Check current supplements to ensure not accidentally overdosing (esp. B6)
 - Check Natural Medicines Database for drug-drug interactions and neurotoxic side effects of other substances
- Medicinal cannabis
 - TGA approved but not PBS listed for neuropathic pain
 - Not first (or even second) line therapy
 - Cost > \$100 per week
 - Online/overseas products not regulated, can be harmful and illegal to import without permission




Medicinal cannabis may be suitable for some health conditions, where all other treatments have been unsuccessful. These include:

- chronic non-cancer pain
- epilepsy
- nausea and vomiting

▶ palliative (end-of-life) care

▶ multiple sclerosis due to chemotherapy

Your safety is important. By following these **5 steps**, you and your doctor can work together to reach the best decision for your health.



nps.org.au/medicinal-cannabis

© 2000 NPS MedicineWise Published May 2000, ABN 61 082 004 393 Level (Y46B Elizabeth St, Surry Hills NSW 2010.
Independent NoTo—profit, Evidence based Developed with funding from the Australian Coverment Department of Health. The information provided is not medical advice. Donot use it be treat or diagnose your own or another person's medical condition and never ignore medical advice or delay seeking is because of something herein. Medicines information changes, and may not be accurate when you access it. To the fulled permitted by law, NPS MedicineWise disclaims all liability (including without limitation for negligence) for any loss, damage, or injury resulting from elizaces on or use of this information NPS/PISF.

